Evidence map›Paper›PMID 33682832›Full record

ArticleActa bio-medica : Atenei Parmensis2020

Synchronous and metachronous colorectal liver metastases: impact of primary tumor location on patterns of recurrence and survival after hepatic resection.

Ingrid Garajova, Rita Balsano, Chiara Tommasi, Raffaele Dalla Valle, Giuseppe Pedrazzi, Matteo Ravaioli, Andrea Spallanzani, Francesco Leonardi, Chiara Santini, Francesco Caputo and 3 more

Open access · greenAbstract read
In one paragraph

Article in Acta bio-medica : Atenei Parmensis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Ingrid GarajovaMedical Oncology Unit, University Hospital of Parma. ingegarajova@gmail.com.
Rita BalsanoMedical Oncology Unit, University Hospital of Parma. rita.balsano@studenti.unipr.it.
Chiara TommasiMedical Oncology Unit, University Hospital of Parma. chiara.tommasi@studenti.unipr.it.
Raffaele Dalla ValleDepartment of Medicine and Surgery - University of Parma. raffaele.dallavalle@unipr.it.
Giuseppe PedrazziDepartment of Medicine and Surgery - University of Parma. giuseppe.pedrazzi@gmail.com.
Matteo Ravaioli3Department of General Surgery and Transplantation, Sant'Orsola-Malpighi Hospital, University of Bologna. matteo.ravaioli@aosp.bo.it.
Andrea SpallanzaniDepartment of Oncology and Hematology, University Hospital of Modena. andrea.spallanzani@gmail.com.
Francesco LeonardiMedical Oncology Unit, University Hospital of Parma. il-france@hotmail.it.
Chiara SantiniDepartment of Oncology and Hematology, University Hospital of Modena. santini.chiara.90@gmail.com.
Francesco CaputoDepartment of Oncology and Hematology, University Hospital of Modena. francesco1990.caputo@libero.it.
Mattia Riefolo5Pathology Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Sant'Orsola-Malpighi Hospital, University of Bologna. mattia.riefolo@unibo.it.
Mario GiuffridaDepartment of Medicine and Surgery - University of Parma. mario.giuffrida4@gmail.com.
Fabio GelsominoDepartment of Oncology and Hematology, University Hospital of Modena. fabiogelsomino83@yahoo.it.
University Hospitals Parma Medical Center · USUniversity of Parma · ITAzienda Unita' Sanitaria Locale Di Modena · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITOspedale San Giuseppe · ITUniversity of Modena and Reggio Emilia · ITYahoo (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConsiderable differences in terms of prognosis exist between the right-sided (RCC) and the left-sided colon cancer (LCC). Aim of the work: In this study, we evaluated prognostic implications of primary tumor location (PTL) among patients who underwent curative-intent hepatectomy for synchronous (SM) and metachronous (MM) colorectal liver metastases (CRLM).

methodsThe study population included all consecutive patients affected by CRLM scheduled for first liver resection at three Italian oncological centers.

resultsA total of 204 patients who underwent CRLM resection were included, 50% with RCC. Synchronous lesions were prevalent (n=133, 65%). Median OS was respectively 40.3 months for SM-RCC, 53.5 months for SM-LCC, 64.5 months for MM-RCC and 81.6 months for MM-LCC. Patients with MM-LCC showed an OS better than patients with SM-RCC (p=0.008) and SM-LCC (p=0.002). PTL had no influence on RFS. RCC group had less recurrences (75% vs 86.5%), though further surgery with curative-intent was possible more in LCC group (29.3% vs 32.5%). Cox proportional hazards model analysis showed that age and the presence of SM vs MM was associated with a significantly higher hazard ratio (HR) for death (HR=1.024; 95%CI=1.005-1.043; p=0.011 and HR=2.010; 95%CI=1.328-3.043; p=0.001, respectively).

conclusionsWe confirmed that patients with CRLM and right-sided primary colon cancer experience worse survival after hepatic resection. The timing of metastasis has been revealed as important prognostic factor.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsAdultAgedAged, 80 and overFemaleHepatectomyHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisSurvival Rate

Identifiers

PMID33682832
PMCPMC7975968
OpenAlexW3133845616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.